NCT07439653

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Phase IRecruitingTORL Biotherapeutics, LLC

Histologically Confirmed Relapsed Or Refractory B-cell Non-hodgkin Lymphoma
Lymphoma, B-cell

See how this trial matches your record

Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Interventions

DRUGTORL-5-700
DRUGTORL-5-700 at MTD/RP2D
DRUGTORL-5-700 at MTD/RP2D in combination with another agent

Eligibility

Inclusion criteria

Must be at least 18 years old

Locations

California

UCLA
Santa Monica, California
Stanford University
Stanford, California

Tennessee

Sarah Cannon Research Institute
Nashville, Tennessee